Bibliography
- Huber CG, Naber D, Lambert M. Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother 2008;9(12):2027-38
- Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
- Lindenmayer JP, Khan A. Pharmacological treatment strategies for schizophrenia. Expert Rev Neurother 2004;4(4):705-23
- Buckley PF, Wiggins LD, Sebastian S, Singer B. Treatment-refractory schizophrenia. Curr Psychiatry Rep 2001;3(5):393-400
- Schimmelmann BG, Conus P, Edwards J, et al. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005;66(10):1239-46
- Andreasen NC, Carpenter WT JR, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162(3):441-9
- Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatr Serv 2005;56:735-42
- Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227-40
- Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54
- Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(Suppl 22):7-11
- Nierenberg AA, Dececco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):5-9
- National Institute for Clinical Excellence (editors). Clinical Guideline 1 Schizophrenia Core Interventions in the Treatment and Mangement of Schizophrenia in Primary and Secondary Care. London: National Institute for Clinical Excellence; 2002
- American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 249-440
- Royal Australian and New Zealand College of Psychiatrists. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39(1/2):1-30
- American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 525-612
- Royal Australian And New Zealand College Of Psychiatrists. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004;38(5):280-305
- American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 440-524
- Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-80
- Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112(2):141-8
- Lambert M, Conus P, Naber D, et al. Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone. Int J Psychiatry Clin Pract 2005;9(4):244-50
- Lambert M, Conus P, Schimmelmann BG, et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 2005;38(5):206-13
- Pantelis C, Lambert TJ. Managing patients with ‘treatment-resistant’ schizophrenia. Med J Aust 2003;178(Suppl):S62-6
- Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
- Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004;26(12):1994-2002
- Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160(6):1125-32
- Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res 2004;66(2/3):143-50
- Lindenmayer JP, Czobor P, Volavka J, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002;63(10):931-5
- Lambert M, Naber D, editors. Current schizophrenia. Hamburg: Science Press; 2004
- Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(6):1330-6
- Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002;63(5):420-4
- Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158(4):518-26
- Ciapparelli A, Dell'osso L, Bandettini Di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003;64(4):451-8
- Pickar D, Bartko JJ. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. Am J Psychiatry 2003;160(6):1133-8
- Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159(2):255-62
- Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-72
- Fabrazzo M, La Pia S, Monteleone P, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 2002;27(6):1050-5
- Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61(Suppl 8):14-7; discussion 18-9
- Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005;20(5/6):409-15
- Williams L, Newton G, Roberts K, et al. Clozapine-resistant schizophrenia: a positive approach. Br J Psychiatry 2002;181:184-7
- Kämpf P, Agelink MW, Mas R, et al. Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability. German J Psychiatry 2003;6(3):64-8
- Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol 2005;19(3):301-5
- Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28(2):66-71
- Lerner V, Libov I, Kotler M, Strous RD. Combination of ‘atypical’ antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(1):89-98
- Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 2000;23(5):284-6
- Valmaggia LR, Van Der Gaag M, Tarrier N, et al. Cognitive–behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. Br J Psychiatry 2005;186:324-30
- Sensky T, Turkington D, Kingdon D, et al. A randomized controlled trial of cognitive–behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000;57(2):165-72
- Fitzgerald PB, Benitez J, Daskalakis JZ, et al. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. J Clin Psychopharmacol 2005;25(4):358-62
- Perlis RH. The role of pharmacologic treatment guidelines for bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):37-47
- Bowden CL. Treatment options for bipolar depression. J Clin Psychiatry 2005;66(Suppl 1):3-6
- Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161(9):1537-47
- Kilzieh N, Akiskal HS. Rapid-cycling bipolar disorder. An overview of research and clinical experience. Psychiatr Clin North Am 1999;22(3):585-607
- Colom F, Vieta E. A perspective on the use of psychoeducation, cognitive–behavioral therapy and interpersonal therapy for bipolar patients. Bipolar Dis 2004;6(6):480-6
- Perry A, Tarrier N, Morriss R, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999;318(7177):149-53
- Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60(4):402-7
- Vieta E. The package of care for patients with bipolar depression. J Clin Psychiatry 2005;66(Suppl 5):34-9
- Miklowitz DJ, Simoneau TL, George EL, et al. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000;48(6):582-92
- Ros S, Aguera L, De La Gandara J, et al. Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand Suppl 2005;(428):14-24, 36
- Quitkin FM, Mcgrath PJ, Stewart JW, et al. Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology 1996;15(4):390-4
- Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001;62(Suppl 18):12-7
- Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1):38S-58S
- Kennedy JS, Jeste D, Kaiser CJ, et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003;18(11):1013-20
- Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 18):4-11
- Rojo JE, Ros S, Aguera L, et al. Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl 2005;(428):25-31, 36
- Klein N, Sacher J, Wallner H, et al. Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics. CNS Spectr 2004;9(11):823-32
- Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):30-40
- Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):13-21
- Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66(10):1216-20
- Malhi GS, Berk M, Bourin M, et al. A typical mood stabilizers: a ‘typical’ role for atypical antipsychotics. Acta Psychiatr Scand Suppl. 2005;(426):29-38
- Thase ME. Treatment of severe depression. J Clin Psychiatry 2000;61(Suppl 1):17-25
- Mcpherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 2005;111(5):331-40
- Avery DH, Holtzheimer PE III, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006;59(2):187-94
- Rossini D, Lucca A, Zanardi R, et al. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 2005;137(1/2):1-10
- Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005;66(9):1097-104